Assistant

Ask questions, navigate pages, or type / for commands

Ask
Navigate
Command

Rakovina Therapeutics Inc.RKV.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · rakovinatherapeutics.com

Rakovina Therapeutics Inc. is a biopharmaceutical research company engaged in developing cancer treatments targeting DNA-damage response systems. The company's pipeline includes the kt-2000 series (oral PARP inhibitors), kt-3000 series (dual PARP/HDAC inhibitors), kt-4000 series (targeted DNA damage inducers), and kt-5000 series (brain-penetrant dual ATR-mTOR inhibitors), leveraging AI platforms to accelerate drug discovery. The company is headquartered in Vancouver, Canada.

Key ratios

ROA
-79.6%TTM
2025 -98.8%2024 -41.6%2023 -27.5%2022 -23.8%
ROE
-1352.3%TTM
2025 -391.1%2024 -102.3%2023 -54.0%2022 -38.4%

Recent news

Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member 2026-09-17 · GlobeNewswireRakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors 2026-09-10 · GlobeNewswireRakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update 2026-08-31 · GlobeNewswireRakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement 2026-08-31 · GlobeNewswireRakovina Therapeutics Announces Results from 2026 Annual General Meeting 2026-08-19 · GlobeNewswireRakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement 2026-08-12 · GlobeNewswireRakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update 2026-06-01 · GlobeNewswireRakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update 2026-04-30 · GlobeNewswireRakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting 2026-04-22 · GlobeNewswire
Track RKV.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer

An unhandled error has occurred. Reload 🗙